phrykt

Tonix Pharmaceuticals Holding Corp. (TNXP): who owns it and who trades it

As of Nov 16, 2026, TNXP insiders reported 8 purchases worth $479K in the last 12 months. The largest buyer was Seth Lederman (CEO), with $393K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Tonix Pharmaceuticals Holding

From the latest filings

Overall: more buying than selling. Famous investors mostly sold. Funds and insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TNXP

102 funds and institutions reported TNXP shares worth $120M at the end of Q2 2026, about 70% of the company. The largest holder is BlackRock, Inc. with 10.4%.

Funds and institutions (13F) 70%Everyone else 30%

10 largest owners, by share of the company

BlackRock, Inc.10.4%
Point72 Asset Management, L.P.8.7%
Millennium Management LLC7.2%
AQR Capital Management LLC6.6%
Vanguard Capital Management LLC5.2%
Jones Hill Capital LP4.7%
Geode Capital Management, LLC2.9%
Ishara Investments LP2.5%
State Street Corp2.0%
UBS Group AG1.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.1.40M10.43%$17.8M+44%
Point72 Asset Management, L.P.1.17M8.70%$14.9M+830%
Millennium Management LLC966,9327.21%$12.3M+340%
AQR Capital Management LLC882,5956.58%$11.3M+447%
Vanguard Capital Management LLC691,8955.16%$8.8M+33%
Jones Hill Capital LP625,4284.67%$8M+38%
Geode Capital Management, LLC395,2602.95%$5M+26%
Ishara Investments LP338,2502.52%$4.3MNew
State Street Corp271,3742.02%$3.5M+18%
UBS Group AG231,6821.73%$3MNo change
Citadel Advisors LLC195,8591.46%$2.5M-58%
Essex Investment Management Co LLC165,1441.23%$2.1MNew
Balyasny Asset Management L.P.132,5910.99%$1.7M-58%
Northern Trust Corp120,3860.90%$1.5M+20%
Nuveen, LLC117,4470.88%$1.5M+24%
Vanguard Fiduciary Trust Co102,0540.76%$1.3M+21%
Goldman Sachs Group Inc98,3560.73%$1.3M+85%
Vanguard Portfolio Management LLC97,9540.73%$1.2M+25%
FMR LLC (Fidelity)93,5510.70%$1.2M+5283%
Ieq Capital, LLC92,3730.69%$1.2M+543%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TNXP insiders reported $479K of open-market purchases and $0 of sales.

Purchases, 12 months
$479K
8 trades, 4 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 12, 2026

Purchases and sales by month

$286K$286KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026Seth LedermanCEOPurchase5,000$4.05$20.3KForm 4
Aug 27, 2026Seth LedermanCEOPurchase2,000$13.79$27.6KForm 4
Aug 20, 2026Richard H BaggerDirectorPurchase1,000$12.60$12.6KForm 4
Jun 12, 2026Carolyn E. TaylorDirectorPurchase1,415$10.55$14.9KForm 4
Jun 9, 2026Seth LedermanCEOPurchase5,000$11.79$58.9KForm 4
Jun 8, 2026Richard Newcomb StillwellDirectorPurchase5,000$11.65$58.2KForm 4
Mar 31, 2026Seth LedermanCEOPurchase5,000$12.62$63.1KForm 4
Mar 18, 2026Seth LedermanCEOPurchase15,000$14.89$223KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Seth LedermanChief Executive Officer, Director$393K–Nov 11, 2026
Richard Newcomb StillwellDirector$58.2K–Jun 8, 2026
Carolyn E. TaylorDirector$14.9K–Jun 12, 2026
Richard H BaggerDirector$12.6K–Aug 20, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TNXP short interest

High short interest. 19.3% of TNXP shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 42%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.32M TNXP shares were sold short, 19.3% of the shares outstanding, up 12.8% from the report before. At the average daily volume of 802,002 shares, buying them all back would take about 4.1 trading days (days to cover).

Shares short, % of all shares

19.3%May 15Oct 3028.4%

Days to cover

4.1May 15Oct 309.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.32M19.35%+13%802,0024.1
Oct 15, 20262.94M17.15%+0%1.22M2.4
Sep 30, 20262.94M17.13%+3%497,6905.9
Sep 15, 20262.84M16.55%-8%348,8778.1
Aug 31, 20263.10M18.09%-9%486,6626.4
Aug 14, 20263.41M19.87%-5%490,6617.0
Jul 31, 20263.60M26.87%+0%500,4297.2
Jul 15, 20263.58M26.74%+0%495,9387.2
Jun 30, 20263.58M26.72%+16%586,9076.1
Jun 15, 20263.08M22.99%+7%615,3845.0
May 29, 20262.87M21.39%+22%460,9366.2
May 15, 20262.34M17.48%-10%461,1245.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Tonix Pharmaceuticals Holding company events

Tonix Pharmaceuticals Holding filed 35 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, auditor). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Oct 15, 2026AnnouncementThe information included in Item 2.02 is incorporated herein by reference. Filing
  3. Oct 2, 2026AnnouncementTonix Pharmaceuticals Holding Corp. received a notice from Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, “DRL”) stating that DRL filed an Abbreviated New Drug Application containing a Paragraph IV patent certification with the U.S. Food and Drug Administration for… Filing
  4. Sep 22, 2026AnnouncementTonix Pharmaceuticals Holding Corp. announced it entered into an agreement with a pharmacy benefit manager, effective immediately, that provides coverage for TONMYA® to approximately 21 million Medicare Part D plan beneficiaries. Filing
  5. Sep 8, 2026AnnouncementTonix Pharmaceuticals Holding Corp. announced the appointment of Thomas Englese as the Company’s Chief Commercial Officer, effective immediately. Filing
  6. Aug 18, 2026LeadershipThe Board of Directors of Tonix Pharmaceuticals Holding Corp. appointed Dr. Seth Lederman, the Company’s President and Chief Executive Officer, as the Company’s Interim Chief Medical Officer. Filing
  7. Aug 10, 2026ResultsReleased financial results. Filing
  8. Aug 3, 2026AnnouncementThe Company announced receipt of official minutes from the Type C meeting with the FDA to discuss the Company’s plans for an adaptive Phase 2 field study of TNX-4800 to prevent Lyme disease in adults in the U.S. The official FDA minutes indicate alignment between the Company and the FDA on a… Filing
  9. Jul 21, 2026LeadershipDr. Gregory M. Sullivan informed Tonix Pharmaceuticals Holding Corp. that he will retire from his role as Chief Medical Officer of the Company, effective August 20, 2026. Filing
  10. Jul 13, 2026AnnouncementThe Company announced it entered into an agreement with a PBM, effective January 1, 2027, that provides coverage for TONMYA to approximately 9 million Medicare Part D plan beneficiaries. Filing
  11. Jun 29, 2026AnnouncementThe Company announced that the first participant was enrolled in the HORIZON Study. Filing
  12. Jun 8, 2026AnnouncementThe Company announced it entered into an agreement with a GPO, effective June 1, 2026, that provides coverage to approximately 17 million U.S. commercially insured individuals, with standard utilization management criteria, for TONMYA. To date, TONMYA is available under Medicaid in most states… Filing
  13. May 27, 2026AnnouncementThe Company announced the publication of the Manuscript, which reports findings from a single-center, first-in-human, Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose escalation study in 26 healthy adult volunteers of the Company’s TNX-1500 product candidate, a… Filing
  14. May 15, 2026AnnouncementThe Company presented the following analysis of pharmacokinetic data from the Phase 1 trial for TNX-4800 at the Global Lyme Alliance in connection with the proposed adaptive Phase 2 field study for TNX-4800, planned for the first half of 2027, pending agreement by the U.S. Food and Drug… Filing
  15. May 11, 2026ResultsReleased financial results. Filing
  16. May 7, 2026LeadershipTonix Pharmaceuticals Holding Corp. held its annual meeting of shareholders. Filing
  17. May 6, 2026AnnouncementThe Company announced it entered into an agreement with a GPO, effective May 1, 2026, that provides coverage to approximately 35 million U.S. commercially insured individuals, with standard utilization management criteria, for TONMYA. To date, TONMYA is covered under Medicaid in 38 states… Filing
  18. May 1, 2026AnnouncementThe information included in Item 2.02 is incorporated herein by reference. Filing
  19. Apr 29, 2026AnnouncementThe Company announced program updates on its TNX-4800 product candidate for protection against Lyme disease, and presented TNX-4800 Phase 1 data at the 4 th Annual Ticks and Tickborne Diseases Symposium. Filing
  20. Apr 23, 2026AnnouncementThe Company’s collaborators at Columbia University presented an oral presentation on the Company’s preclinical TNX-1700 program at the AACR entitled TFF2 Deficiency Amplifies IL-1β–Driven Inflammation and Promotes Aging-Associated Gastric Tumor Progression, which reviewed the results of a… Filing
  21. Mar 31, 2026AnnouncementThe Company announced program updates on its TNX-4800 product candidate for protection against Lyme disease, including the announcement that Phase 1 data of TNX-4800 was presented by Mark S. Klempner, MD, professor of medicine at UMass Chan Medical School, an inventor of TNX-4800 and principal… Filing
  22. Mar 26, 2026AnnouncementThe Company announced that the first participant was dosed in a Phase 1 investigator-initiated study to evaluate the effect of TNX-1900 on trigeminal nerve-mediated vasodilation of the forehead using capsaicin and electrical stimulation, a model for trigeminal neurovascular reactivity, in healthy… Filing
  23. Mar 18, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  24. Mar 13, 2026ResultsReleased financial results. Filing
  25. Mar 10, 2026AnnouncementOn March 10. 2026, the Company announced two oral presentations on TONMYA TM at the ICCF. The first presentation, “Cyclobenzaprine HCl Sublingual Tablets (CBP SL) Provide Rapid Pain Relief in Adults with Fibromyalgia”, presented data on the RESILIENT trial, a 14-week, randomized, placebo-controlled… Filing
  26. Mar 3, 2026AnnouncementThe Company announced that it received approval from Nasdaq to transfer the listing of its common stock from The Nasdaq Capital Market to The Nasdaq Global Select Market commencing at the open of market on March 3, 2026. Filing
  27. Feb 3, 2026AnnouncementThe information included in Item 2.02 is incorporated herein by reference. Filing
  28. Dec 29, 2025AgreementTonix Pharmaceuticals Holding Corp. entered into a securities purchase agreement with a single institutional investor. Filing
  29. Dec 29, 2025AnnouncementThe Company announced that it plans to meet with the U.S. Food and Drug Administration in 2026 to explore Phase 2/3 development options for TNX-4800. Filing
  30. Dec 16, 2025AnnouncementThe Company announced that it licensed exclusive worldwide rights to TNX-4900 (formerly known as PW507), a highly selective small-molecule Sigma-1 receptor antagonist with demonstrated analgesic activity in multiple animal models of neuropathic pain, from Rutgers University. Filing
  31. Dec 9, 2025AnnouncementThe Company announced the appointment of Irina Ishak as General Counsel, effective immediately. Filing
  32. Nov 24, 2025AnnouncementThe Company announced that the FDA cleared the IND application to support clinical development of TNX-102 SL 5.6 mg for the treatment of MDD in adults. Filing
  33. Nov 21, 2025AgreementTonix Pharmaceuticals Holding Corp. amended its Sales Agreement with A.G.P./Alliance Global Partners, dated as of June 11, 2025 (as amended, the “Sales Agreement”), to allow for an increase to the maximum aggregate offering price of shares issuable under the Sales Agreement. Filing
  34. Nov 18, 2025AnnouncementTonix Pharmaceuticals Holding Corp.’s Board of Directors approved an increase to its share repurchase program pursuant to which the Company may repurchase up to an additional $25.0 million in value of its outstanding common stock, bringing total authorized shares under the program to $35 million. Filing
  35. Nov 17, 2025AnnouncementThe Company announced that TONMYA TM is commercially available at pharmacies by prescription in the United States. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Tonix Pharmaceuticals Holding financials

Famous investors that hold TNXP

3 of the 50 well-known investors we track reported holding TNXP in their latest 13F filing. The largest position is Steve Cohen's, worth $10.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20261.12M$10.9M0.0%-4%
Israel Englander · Millennium ManagementQ3 2026818,779$8M0.0%-15%
Ken Griffin · Citadel AdvisorsQ3 2026337,434$3.3M0.0%+72%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named TNXP in the last 120 days.

FiledHolderFormStake
Nov 13, 2026AQR Capital Management, LLC13G/A3.9%
Nov 13, 2026AQR Capital Management, LLC13G/A3.9%

Questions about Tonix Pharmaceuticals Holding Corp. (TNXP) stock

Who owns the most TNXP stock?

The largest reported owner of Tonix Pharmaceuticals Holding Corp. (TNXP) is BlackRock, Inc., with 10.4% of the company. In total, 102 funds and institutions reported holding TNXP at the end of Q2 2026, together about 70% of the shares. See the largest owners.

Are TNXP insiders buying or selling?

In the last 12 months, TNXP insiders reported 8 open-market purchases worth $479K and no sales. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in TNXP?

As of Oct 30, 2026, 3.32M TNXP shares were sold short, 19.3% of the shares outstanding, up 12.8% from the report before. At the average daily volume of 802,002 shares, buying them all back would take about 4.1 trading days (days to cover). See the history.

Which famous investors hold TNXP?

3 of the 50 well-known investors we track reported TNXP in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $10.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.